+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Programmed Cell Death Protein"

Tie-2 modulators - Pipeline Insight, 2024 - Product Thumbnail Image

Tie-2 modulators - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
RET (Ret Proto-Oncogene) protein Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

RET (Ret Proto-Oncogene) protein Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Hematopoietic progenitor kinase 1 inhibitors - Pipeline Insight, 2024 - Product Thumbnail Image

Hematopoietic progenitor kinase 1 inhibitors - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 60 Pages
  • Global
From
From
From
From
From
Global PARP Inhibitor Market - Product Thumbnail Image

Global PARP Inhibitor Market

  • Report
  • May 2024
  • 200 Pages
  • Global
From
Global Immuno-oncology Market - Product Thumbnail Image

Global Immuno-oncology Market

  • Report
  • January 2024
  • 200 Pages
  • Global
From
From
From
Loading Indicator

Programmed Cell Death Protein (PDP) is a type of protein that plays a role in the regulation of cell death in the body. It is a key component of the body's natural defense against cancer, as it helps to prevent the growth and spread of cancerous cells. In oncology drugs, PDP is used to target and destroy cancer cells, while leaving healthy cells unharmed. PDP is also used to reduce the side effects of chemotherapy and radiation therapy, as well as to reduce the risk of recurrence of cancer. PDP is also used to reduce the risk of metastasis, or the spread of cancer to other parts of the body. PDP is a rapidly growing market, with many companies developing and marketing PDP-based drugs. Some of these companies include Merck, Bristol-Myers Squibb, AstraZeneca, Novartis, and Pfizer. Show Less Read more